CANCER VACCINES: KAHIMMUNE TACKLES THE "DARK GENOME"
May 14, 2026
"We are targeting a total raise of approximately €18M, structured in stages"
Founded in late 2025, the Avignon biotech signs a scientific collaboration with Gustave Roussy to select its first vaccine candidate in digestive oncology. A funding round has been launched.
If cancer vaccines are not new, their effectiveness remains limited, notably due to target selection and industrialization challenges. Kahimmune Therapeutics, a spin-off of Gustave Roussy and SATT Paris-Saclay launched in late 2025 and based in Avignon, explores a still under-investigated angle of immuno-oncology: exploiting ...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.
Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.
RELATED ARTICLES
ASTHMA: Néovacs (Suresnes) - Oceane convertible bonds to finance its development
To finance the research programs of its vaccine candidates in asthma and food allergy, the company founded in 1993 has raised nearly €40M in the form
RECORD IPO FOR KAILERA THERAPEUTICS
$625 million! That is the amount Kailera Therapeutics raised in its IPO on an euphoric NASDAQ. An amount that surprised not only thecompany, but also
CELLPROTHERA, POST-MYOCARDIAL INFARCTION CELL THERAPY READY TO MOVE TO PHASE 3
After positive phase 2 results in the post-myocardial infarction setting, CellProthera believes it has now assembled the key clinical, regulatory and